learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
- What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata? Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
- Why is tofacitinib considered a medical treatment rather than a cosmetic or preventative hair product? Tofacitinib is a medical treatment because it targets underlying immune conditions affecting hair growth.
- What are the key limitations and considerations surrounding tofacitinib in hair loss products and therapies? Reported hair regrowth with tofacitinib comes from alopecia areata, an autoimmune condition — mostly from small, non-randomized studies, with relapse common after stopping. There is no good evidence it helps pattern hair loss, and it is not approved for hair loss anywhere.
- All 5 questions on Tofacitinib →
